Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel...
Location: Sweden
Employees: 11-50
Total raised: $2.92M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | Flerie Inv... | flerie.com |
| - | Almi Inves... | almi.se |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.02.2026 | - | $2.92M | European I... |
Mentions in press and media 18
| Date | Title | Description |
| 23.02.2026 | Glioblastoma Fight Accelerates: Beactica and KU Leuven Secure €2.5M for Orphan Drug BEA-17 | Beactica Therapeutics and KU Leuven secured a substantial €2.5 million EIC grant. This vital funding accelerates the development of orphan drug BEA-17. BEA-17 is a groundbreaking, first-in-class precision immune therapy targeting glioblasto... |
| 17.02.2026 | Beactica Therapeutics Secures €2.5 Million EIC Grant To Advance Orphan Drug BEA-17 Toward Clinical Trials | Beactica Therapeutics AB and KU Leuven have secured €2.5 million in non-dilutive funding from the European Innovation Council (EIC) to advance BEA-17, a first-in-class precision immune therapy for glioblastoma, toward clinical readiness. Th... |
| 17.02.2026 | Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness | Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness Tue, Feb 17, 2026 07:00 CET Report this content Uppsala, Sweden – 17 February 2026 Beactica Therapeutics ... |
| 07.10.2025 | Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17 | Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17 Tue, Oct 07, 2025 08:00 CET Report this content Beactica Therapeutics AB, the Swedish precision medicine company, today an... |
| 14.02.2024 | Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024 | Beactica Therapeutics’ TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024 Wed, Feb 14, 2024 08:17 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology company, today a... |
| 26.09.2023 | Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences | Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences Tue, Sep 26, 2023 08:00 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology company, today announced th... |
| 12.09.2023 | Beactica Therapeutics strengthens its preclinical development team | Beactica Therapeutics strengthens its preclinical development team Tue, Sep 12, 2023 08:00 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology company, today announced two appointments to its preclinical develop... |
| 05.09.2023 | Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate | Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate Tue, Sep 05, 2023 07:30 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology company, today announced the selection of BEA-17 as ... |
| 19.06.2023 | Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities | Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities Mon, Jun 19, 2023 09:00 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology comp... |
| 16.05.2023 | Beactica Therapeutics to present breakthrough in YAP–TEAD programme at the Hippo Pathway Drug Development Summit 2023 | Beactica Therapeutics to present breakthrough in YAP–TEAD programme at the Hippo Pathway Drug Development Summit 2023 Tue, May 16, 2023 10:00 CET Report this content Beactica Therapeutics AB, the Swedish precision oncology company, today an... |
Show more